加味当归贝母苦参丸辅助经肝动脉化疗栓塞术治疗原发性肝癌临床的研究.docVIP

加味当归贝母苦参丸辅助经肝动脉化疗栓塞术治疗原发性肝癌临床的研究 　　摘要：目的 观察加味当归贝母苦参丸辅助经肝动脉化疗栓塞术治疗原发性肝癌的临床疗效。方法 将原发性肝癌患者84 例随机分为联合治疗组和常规对照组各42 例。常规对照组采用经肝动脉化疗栓塞术治疗，联合治疗组在此基础上给予加味当归贝母苦参丸汤剂辨证加减。比较2组患者肿瘤体积、生活质量评分、中医证候积分、免疫功能指标及不良反应。结果 2组各有37例患者完成临床观察。3个疗程结束时，肿瘤客观反应率联合治疗组为91.9%，常规对照组为86.4%。2组患者治疗后临床症状（发热、呕吐、腹痛、乏力）均显著改善（P0.05），联合治疗组优于常规对照组（P0.05）。联合治疗组治疗后卡氏评分升高（P0.05），高于常规对照组（P0.05）。联合治疗组治疗后Th1功能水平升高（P0.05），高于常规对照组（P0.05）。联合治疗组肝功能和消化道不良反应低于常规对照组（P0.05）。结论 加味当归贝母苦参丸对化疗栓塞治疗原发性肝癌具有增效作用，并且能够减少不良反应，提高患者的生存质量。 　　关键词：加味当归贝母苦参丸；原发性肝癌；经肝动脉化疗栓塞术；临床研究 　　DOI：10.3969/j.issn.1005-5304.2015.05.010 　　中图分类号：R273.57 文献标识码：A 文章编号：1005-5304（2015）05-0033-04 　　Abstract：Objective To evaluate the clinical efficacy of modified Angelica Fritilaria Sophorae Pill assisting transcatheter arterial chemoembolization （TACE） to treat primary liver cancer. Methods Totally 84 patients with primary liver cancer were randomized into combination treatment group （42 cases） and conventional control group （42 cases）. The conventional control group received TACE treatment， the combination treatment group received modified Angelica Fritilaria Sophorae Decoction and TACE. The tumor volume， TCM syndrome score， life quality， immune function and toxicity reaction of both groups were observed. Results Clinical observation was completed with 37 patients in each group. After three courses of treatment， the objective tumor response rate was 91.9% in combination treatment group and 86.4% in conventional control group （P0.05）. The clinical symptoms （fever， abdominal pain， vomiting， fatigue） in both groups were improved （P0.05）， with significant difference between the two groups （P0.05）. After treatment， KPS scores increased （P0.05） in combination treatment group， and the scores of combination treatment group were significantly higher than those of the conventional control group （P0.05）. After treatment， Th1 function level increased （P0.05） in combination treatment group， and that was better than the conventional control group （P0.05）. The incidence